XML 103 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended 20 Months Ended
Oct. 31, 2021
Oct. 16, 2021
Jul. 01, 2021
Dec. 31, 2022
Apr. 30, 2022
May 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Nov. 30, 2020
Aug. 31, 2021
Aug. 12, 2021
Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total transaction price $ 50,900,000                        
Proceeds from related party $ 5,000,000.0                        
Deferred revenue       $ 39,417,000     $ 39,417,000 $ 20,370,000 $ 34,937,000        
Deferred revenue — current       1,733,000     1,733,000 827,000          
Deferred revenue - non-current       37,684,000     37,684,000 19,543,000          
Total revenue from UT             99,770,000 75,442,000 65,144,000        
Collaborations and services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT             27,924,000 36,274,000 32,820,000        
AFREZZA product sales                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT             56,247,000 39,168,000 32,324,000        
United Therapeutics Corporation                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT             42,851,000 34,412,000 32,213,000        
United Therapeutics Corporation | Manufacturing Services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Funding for development of alternative manufacturing processes       2,300,000 $ 700,000                
United Therapeutics Corporation | Commercialization And Continuous Improvement Activities                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Funding for capital improvements       39,500,000 2,300,000                
Collaboration and License Agreement | United Therapeutics Corporation                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront payment received                         $ 45,000,000.0
Milestone Payment Received                   $ 12,500,000      
Total transaction price       50,900,000     50,900,000            
Total anticipated cash flows [1]   $ 463,500,000   722,300,000 483,200,000   722,300,000            
Deferred revenue       18,600,000     18,600,000 37,900,000          
Deferred revenue — current       600,000     600,000 1,600,000          
Deferred revenue - non-current       18,000,000.0     18,000,000.0 36,300,000          
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Revenue recognized during period               0          
Allocated transaction price   144,500,000   722,300,000 483,200,000                
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total anticipated cash flows   64,300,000   120,000,000.0 71,500,000   120,000,000.0            
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total anticipated cash flows   $ 399,200,000   602,300,000 $ 411,700,000   602,300,000            
Collaboration and License Agreement | United Therapeutics Corporation | Clinical Supplies                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total transaction price       105,800,000     105,800,000            
Collaboration and License Agreement | United Therapeutics Corporation | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Additional option exercise and development milestone payments to be receive       40,000,000.0     $ 40,000,000.0            
Collaboration and License Agreement | Tyvaso DPI                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total anticipated cash flows                     $ 221,500,000 $ 221,500,000  
Commercial Supply Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Amendment description             As amended , the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) United Therapeutics provides notice to the Company at least 24 months in advance of such renewal that United Therapeutics does not wish to renew the CSA or (ii) the Company provides notice to United Therapeutics at least 48 months in advance of such renewal that the Company does not wish to renew the CSA.            
Commercial Supply Agreement | United Therapeutics Corporation                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT             $ 24,826,000 267,000          
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT [2]             24,826,000 267,000          
Co-Promotion Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Impairment on contract assets related to variable consideration               100,000          
Co-Promotion Agreement | Collaborations and services                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Reserve for allowance for doubtful accounts               800,000          
Co-Promotion Agreement | Vertice Pharma LLC                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total transaction price       6,300,000     6,300,000            
Amendment to Co Promotion Agreement | Vertice Pharma LLC                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Percentage of modification of previously fixed consideration     50.00%                    
Supply and Distribution Agreement | AFREZZA product sales | Biomm                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT             0 0 200,000        
License and Distribution Agreement | Cipla Ltd                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Deferred revenue       1,500,000     1,500,000 1,700,000          
Deferred revenue — current       100,000     100,000 100,000          
Deferred revenue - non-current       $ 1,400,000     1,400,000 1,600,000          
Marketing and distribution agreement date           2018-05              
License and Distribution Agreement | Collaborations and services | Cipla Ltd                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Total revenue from UT             $ 147,000 $ 147,000 $ 147,000        
[1]

The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.
[2]

Amount consists of revenue recognized for Manufacturing Services and sales of product to UT for the periods presented.